SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE

Rhea-AI Summary

SOHM Inc. (OTC PINK:SHMN) has announced significant developments in its biotechnology operations. The company is expanding its ABBIE genome editing and cell engineering program at their Carlsbad facility and UACI labs to support growing Next-Generation Sequencing (NGS) validation requirements.

The strategic expansion aims to meet increasing demands for engineered mouse models and cell lines important for drug development, gene therapy, and immunotherapy. The company is also enhancing its AI-enabled ABBIE platform for next-generation gene editing applications.

Additionally, SOHM will present a poster titled 'ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration' at the American Society of Gene and Cell Therapy Conference, scheduled for May 13-17 in New Orleans, LA.

CHINO HILLS, CA / ACCESS Newswire / April 10, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, is thrilled to announce and share some exciting developments at SOHM Inc.! Our commitment to innovation and excellence continues to drive our growth, and we are delighted to announce the expansion of our ABBIE genome editing and cell engineering program at our Carlsbad facility along with our UACI labs.

This expansion is a strategic move to support our ever-growing Next-Generation Sequencing (NGS) validation needs. With an increasing number of licensing opportunities on the horizon, we are poised to meet the demand for engineered mouse models and cell lines vital for drug development, gene therapy, and immunotherapy. Additionally, this expansion will enhance our AI-enabled ABBIE platform, paving the way for revolutionary applications in next-generation gene editing. Dr. David Aguilar, COO, added.

We are equally excited to inform you that SOHM Inc. will be presenting a poster at the prestigious American Society of Gene and Cell Therapy Conference, taking place from May 13-17 in vibrant New Orleans, LA. Our poster is entitled "ABBIE Gene Editing: A Breakthrough in Precise, Replicable, and Traceable Genomic Integration," highlighting our cutting-edge advancements in this critical field.

Further details regarding the poster event will be shared in due course, and we look forward to your continued support as we embark on this thrilling journey.

Thank you for being an integral part of SOHM Inc.'s success!

For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com:

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc

View the original press release on ACCESS Newswire

FAQ

What is the purpose of SOHM's (SHMN) ABBIE program expansion at Carlsbad facility?

The expansion supports growing Next-Generation Sequencing validation needs and meets demand for engineered mouse models and cell lines for drug development, gene therapy, and immunotherapy.

When and where will SOHM (SHMN) present their ABBIE Gene Editing research?

SOHM will present at the American Society of Gene and Cell Therapy Conference in New Orleans, LA, from May 13-17, 2025.

What are the key applications of SOHM's (SHMN) ABBIE platform?

ABBIE platform focuses on genome editing, cell engineering, and AI-enabled applications for next-generation gene editing technology.

How is SOHM (SHMN) advancing its gene editing capabilities?

SOHM is expanding its ABBIE program, enhancing its AI-enabled platform, and developing precise, replicable, and traceable genomic integration technologies.

What facilities are involved in SOHM's (SHMN) ABBIE program expansion?

The expansion involves SOHM's Carlsbad facility and UACI labs.